SYNTHESIS, CHARACTERIZATION AND CHOLINESTERASE INHIBITORY EFFECTS OF IBUPROFEN-BASED SPIROTHIAZOLIDINONES
Öz
Anahtar Kelimeler
Kaynakça
- 1. Querfurth, H.W., Laferla, F.M. (2010). Alzheimer’s disease. The New England Journal of Medicine, 362(4), 329-344. [CrossRef]
- 2. Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C.E., Cummings, J., van der Flier, W. (2021). Alzheimer’s disease. Lancet, 397, 1577-1590. [CrossRef]
- 3. Vaz, M., Silvestre, S. (2020). Alzheimer’s disease: Recent treatment strategies. European Journal of Pharmacology, 887, 173554. [CrossRef]
- 4. Davies, N.M. (1998). Clinical pharmacokinetics of ibuprofen. The first 30 years. Clinical Pharmacokinetics, 34, 101-154. [CrossRef]
- 5. Halford, G.M., Lordkipanidzé, M., Watson, S.P. (2012) 50th anniversary of the discovery of ibuprofen: An interview with Dr Stewart Adams. Platelets, 23, 415-422. [CrossRef]
- 6. McGeer, P.L., Guo, J.P., Lee, M., Kennedy, K., McGeer, E.G. (2018). Alzheimer’s disease can be spared by nonsteroidal anti-inflammatory drugs. Journal of Alzheimer's Disease, 62, 1219-1222. [CrossRef]
- 7. Wilkinson, B.L., Cramer, P.E., Varvel, N.H., Reed-Geaghan, E., Jiang, Q., Szabo, A., Herrup, K., Lamb B.T., Landreth, G.E. (2012). Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease. Neurobiology of Aging, 33, 197, e21-32. [CrossRef]
- 8. Cihan-Üstündağ, G., Naesens, L., Şatana, D., Erköse-Genç, G., Mataracı-Kara, E., Çapan, G. (2019). Design, synthesis, antitubercular and antiviral properties of new spirocyclic indole derivatives. Monatshefte Fur Chemie, 150, 1533-1544. [CrossRef]
Ayrıntılar
Birincil Dil
İngilizce
Konular
Farmasotik Kimya
Bölüm
Araştırma Makalesi
Yazarlar
Erken Görünüm Tarihi
22 Aralık 2024
Yayımlanma Tarihi
20 Ocak 2025
Gönderilme Tarihi
30 Mayıs 2024
Kabul Tarihi
17 Eylül 2024
Yayımlandığı Sayı
Yıl 2025 Cilt: 49 Sayı: 1